Vifor Pharma : Full-year results 2020 – Analyst presentation

PRESENTATION

FULL-YEAR RESULTS 2020

ANALYST CALL

3 MARCH 2021, 2:00 PM CET

FULL-YEAR RESULTS 2020

SPEAKERS

STEFAN SCHULZE

CHIEF EXECUTIVE OFFICER

COLIN BOND

CHIEF FINANCIAL OFFICER

BUSINESS UPDATE AND OUTLOOK

STEFAN SCHULZE, CHIEF EXECUTIVE OFFICER

2020 HIGHLIGHTS

KEY MILESTONES ACHIEVED ACROSS ALL AREAS

•  AFFIRM-AHF study of Ferinject® positive readout

•  KALM-2 phase-III study of KORSUVATM 1 positive readout

  CLINICAL TRIALS

•  INNO2VATE phase-III study of vadadustat2 positive readout

•  ACCOLADE phase-II study of avacopan3 readout

•  Recruitment in the phase-II study of VIT-2763 in beta-thalassemia started

MARKET ACCESS

•  Ferinject® launched in Japan

•  China: Ferinject® and Veltassa® partnered & NDA submission accepted for Ferinject®

•  Avacopan3 filing accepted for review in Europe

•  KORSUVATM 1 filed in the US

  BUSINESS DEVELOPMENT

•  In-licensing agreement with Cara Therapeutics for KORSUVATM 1 extended

•  Worldwide rights4 of ANG-3777 licensed from Angion Biomedica

•  Divestment of OM Pharma strengthens focus on key therapeutic areas

1) Licensed from Cara Therapeutics, Inc. 2) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to the US dialysis market 3) Licensed from ChemoCentryx, Inc. 4) Excluding China, Taiwan, Hong Kong and Macau; for all nephrology indications and congestive heart-failure